Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.

Peter A FrithSamiha AshmawiSrikanth KrishnamurthyAlev GurgunSashka HristoskovaVirginia PilipovicAnna Marie HamannArthur BackerPetter OlssonKonstantinos KostikasDina V Diaznull null

Published in: Respirology (Carlton, Vic.) (2018)

FLASH demonstrated that a direct switch to IND/GLY from SFC improved pre-dose FEV1 and FVC in COPD patients with up to one exacerbation in the previous year. No new safety signals were identified.

Keyphrases

chronic obstructive pulmonary disease
randomized controlled trial
end stage renal disease
lung function
newly diagnosed
ejection fraction
chronic kidney disease
study protocol
peritoneal dialysis
extracorporeal membrane oxygenation